1317. Trichomonas vaginalis (TV) prevalence and correlates in Alberta STI Clinic attendees
Session: Poster Abstract Session: Clinical Infectious Diseases: Sexually Transmitted Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • Trich Poster IDSA 2016 FINAL.pdf (897.6 kB)
  • Background: Global estimates of Trichomonas vaginalis(TV) prevalence are variable with few Canadian studies.

    Methods: Specimens collected from January to April, 2016 for gonorrhea (NG) and Chlamydia (CT) screening from urogenital sites among male and female attendees (>17 years old) at two Alberta STI Clinics were tested for TV. The Gen-Probe Aptima Trichomonas vaginalisAssay (Gen-Probe Inc, San Diego, CA) was used to test endocervical, vaginal and urine specimens. For a female sub-population, test results from endocervical and urine specimens collected on the same individuals at the same visit were compared and the proportion of discordant results was calculated. Descriptive analysis of individuals was completed using IBM SPSS Statistics version 19.0 (IBM, Armonk, NY, USA).

    Results: A total of 2,273 individuals were tested. Just over one-half (53.6%; n=1,218) were males, of which 355 (29%) were men who have sex with men (MSM); all tested via urine samples. The male TV prevalence was 0.2% (n=3); all male cases were asymptomatic, and heterosexual. The male prevalence for CT was 5.8% and NG was 1.8%. The overall TV prevalence for females, combining endocervical/vaginal and urine results, was 2.8% (n=29), CT was 5.7% (n=60), and NG was 1.8% (n=19). Only 6/29 (21%) female specimens positive using the Gen-Probe Aptima TV test were positive by wet mount. The TV prevalence among symptomatic women rose to 5.3% (21/397). Correlates associated with TV infection among females were older age (30y vs. 27y, p=0.04), Aboriginal ethnicity (41.4% vs. 11.0%, p<0.001), being symptomatic (72.4% vs. 38.1%; p<0.001), and requiring a pelvic exam (65.5% vs. 41.9%; p=0.01).

    There was high concordance of results between urine and cervical swabs (99.2%); the three (0.8%) specimens that were negative by urine were positive by swabs.

    Conclusion: Our study showed a prevalence of TV of 2.5% in female attendees at two Canadian STI Clinics, which is at the lower end of the range reported in other studies (0.3-30%), but between that of chlamydia and gonorrhea. No cases were identified among MSM and prevalence was very low (0.2%) in heterosexual males, all of whom were asymptomatic. The use of wet mount as a screening test in females would have missed more than 75% of female TV cases.

     

    Jennifer Gratrix, RN, MSc1, Sabrina Plitt, PhD2, Leeann Turnbull, BSc, MLT3, Petra Smyczek, MD, PhD, FRCPC1, Judith Brandley, RN, BN4, Ron Scarrott, RN, BScN5, Prenilla Naidu, MD, FRCPC6, Penny Parker, RN, BN4, Brenda Blore, RN7, Amy Bull, MLT3, Sandy Shokoples, MSc, MLT6, Lindsay Bertholet, MN, RN8, Max Chernesky, PhD9, Ron Read, MD, PhD, FRCPC10 and Ameeta Singh, BMBS, MSc, FRCPC11, (1)Alberta Health Services-Centralized STI Services, Edmonton, AB, Canada, (2)Public Health Agency of Canada, Ottawa, ON, Canada, (3)Provincial Laboratory for Public Health, Edmonton, AB, Canada, (4)Edmonton STI Clinic, Alberta Health Services, Edmonton, AB, Canada, (5)Alberta Health Services - Calgary STI Clinic, Calgary, AB, Canada, (6)Provincial Laboratory for Public Health (Alberta), Edmonton, AB, Canada, (7)Alberta Health Services- Calgary STI Clinic, Calgary, AB, Canada, (8)Alberta Health Services - Centralized STI Services, Edmonton, AB, Canada, (9)McMaster University, Hamilton, ON, Canada, (10)STI Clinic, Alberta Health Services, Calgary, AB, Canada, (11)Medicine/Infectious Diseases, University of Alberta, Edmonton, AB, Canada

    Disclosures:

    J. Gratrix, None

    S. Plitt, None

    L. Turnbull, None

    P. Smyczek, None

    J. Brandley, None

    R. Scarrott, None

    P. Naidu, Hologic Inc: Investigator , Research support and Unrestricted educational grant provided to AMMI-CACMID to pay for accommodation and travel to national meeting

    P. Parker, None

    B. Blore, None

    A. Bull, None

    S. Shokoples, None

    L. Bertholet, None

    M. Chernesky, Hologic Inc: Research Contractor and Speaker's Bureau , Research support

    R. Read, None

    A. Singh, Hologic Inc: Speaker at sponsored symposium , Travel and accommodation to meeting paid by unrestricted educational grant to AMMI CACMID

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.